Phosphorylation of CDC25C at S263 controls its intracellular localisation  by Esmenjaud-Mailhat, Charlotte et al.
FEBS Letters 581 (2007) 3979–3985Phosphorylation of CDC25C at S263 controls its intracellular localisation
Charlotte Esmenjaud-Mailhata,b, Vale´rie Lobjoisa, Carine Fromentc, Roy M. Golsteynb,
Bernard Monsarratc, Bernard Ducommuna,d,*
a LBCMCP-CNRS, IFR109 ‘‘Institut d’Exploration Fonctionnelle des Ge´nomes’’, University of Toulouse, 118 Route de Narbonne,
31062 Toulouse, France
b Institut de Recherche Servier, 125 Chemin de Ronde, 78290 Croissy sur Seine, France
c IPBS-CNRS UMR5089, 205 Route de Narbonne, 31077 Toulouse, France
d CHU Purpan, TSA 40031, 31059 Toulouse Cedex, France
Received 2 June 2007; revised 6 July 2007; accepted 11 July 2007
Available online 23 July 2007
Edited by Giulio Superti-FurgaAbstract CDC25C phosphatase is a key actor in cell cycle pro-
gression that controls the activation of CDK1-cyclin B at mito-
sis. Its activity is known to be highly regulated by a number of
signalling pathway-activated kinases resulting in its phosphory-
lation on multiple residues. In this study, we have puriﬁed
CDC25C from cells and have used a proteomic approach to iden-
tify new regulatory phosphorylations. Here, we report the identi-
ﬁcation by mass spectrometry of a peptide monophosphorylated
on serine 263. We demonstrate by cell imaging that mutation of
S263 to alanine leads to a nuclear accumulation of CDC25C that
is further reinforced by leptomycin-B. We propose that phos-
phorylation at S263 is part of the regulatory mechanism that
modulates nuclear import of CDC25C, thus preventing cyto-
plasm to nucleus shuttling.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The three CDC25 phosphatases (A, B and C) are responsible
for the dephosphorylation and the activation of cyclin-depen-
dent kinases (CDK)-cyclin complexes at the key transitions of
the cell cycle [1–3]. CDC25C is active during late G2 and mito-
sis and plays signiﬁcant roles in the control of the G2–M tran-
sition and the progression into mitosis. The current model
proposes that the CDC25B isoform initially activates CDK1-
cyclin B at the centrosome [4–6], followed by the activation
of CDK1-cyclin B complexes by CDC25C in the nucleus at
the onset of mitosis [7]. Indeed, microinjection of cells with
anti-CDC25C antibodies, or transfection with inactive
CDC25C mutants, prevents entry into mitosis [8,9].
The activity of CDC25C has to be precisely regulated in
order to ensure an accurate triggering of entry into mitosis.
To achieve this eﬃciently, CDC25 phosphatases are highly
regulated at the transcriptional, post-transcriptional and*Corresponding author. Address: LBCMCP-CNRS, IFR109 ‘‘Institut
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doi:10.1016/j.febslet.2007.07.024post-translational level [10]. The carboxy-terminal catalytic
domains of the CDC25A, B and C proteins are highly con-
served compared to their N-terminal non-catalytic regions,
which are globally more divergent. The N-terminal domain is
involved in the regulation of the intracellular localization
and in the turnover of these phosphatases, and is highly phos-
phorylated. Indeed in several instances, multiple phosphoryla-
tion events have been correlated with modulation of the
activity and functional consequence. CDK1 phosphorylates
CDC25C at mitosis and the activity of CDC25C appears to
be highly regulated by an auto-ampliﬁcation mechanism
involving phosphorylation by CDK1-cyclin B [11].
Phosphorylation of CDC25C at S216 by either C-TAK1
during the cell cycle or by the checkpoint kinases CHK1 and
CHK2 in response to DNA injury, creates a 14-3-3 binding site
that causes the cytoplasmic retention of CDC25C thus pre-
venting entry into mitosis [12–17]. It is thought that dissocia-
tion from 14-3-3 at the onset of mitosis allows CDC25C
nuclear import where it activates CDK1-cyclin B. Accordingly,
mutation of S216 to the non-phosphorylatable residue alanine
results in premature entry into mitosis [18]. Furthermore,
phosphorylation of Serine 216 has been shown to be blocked
by the phosphorylation of Serine 214 by CDK1-cyclin B, thus
preventing S216 phosphorylation and 14-3-3 binding [19]. Ser-
ine 216 was also shown to be phosphorylated by the ERK1/
MAP kinase pathway and proposed to be involved in its ubiq-
uitin-dependent degradation [20].
CDC25C subcellular localization is also mediated by a nu-
clear export signal (NES), a nuclear localization sequence
(NLS) and a number of phosphorylation events that are likely
to contribute to its nucleo-cytoplasmic shuttling. Phosphoryla-
tion of T236 by protein kinase CK2 was shown to inhibit the
binding to importin alpha/beta and to prevent nuclear import.
Interestingly, this site is located near the CDC25 nuclear local-
ization signal [21]. CDC25C is phosphorylated by members of
the polo-like kinase (PLK) family. Serine 198 was found to be
phosphorylated in vitro by PLK1 and PLK3 [22,23]. Serine
191 was also found to be phosphorylated by PLK3 [23]. These
studies demonstrated that phosphorylation by PLK resulted in
nuclear accumulation of CDC25C thus suggesting a critical
role for these kinases in the control of the timing of CDC25C
nuclear translocation upon entry into mitosis [22,23].
Phosphorylation of CDC25C by ERK-MAPKinases has
also been reported in Xenopus oocytes CDC25C on three sites
that were found to be phosphorylated during G2–M transitionblished by Elsevier B.V. All rights reserved.
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fully conserved in humans (T48, T67 and S168) and have been
shown, together with two additional sites (S122 and T130), to
be phosphorylated in vivo at mitosis [25,26]. These sites were
suspected to be phosphorylated by CDK1 and thought to reg-
ulate the interaction with regulatory partner such as the prolyl-
isomerase Pin1 [27,28]. Finally, phosphorylation of CDC25C
on S168 by SAPK/JNK was also reported but was associated
with inhibition of CDC25C activity upon stress such as UV
irradiation [29].
The objective of the study reported here was to identify new
sites phosphorylated in intact cells on CDC25C during an
unperturbed cell cycle. To this aim, we have developed a hu-
man CDC25C expression cell line and setup a puriﬁcation
strategy allowing the identiﬁcation of phosphorylated sites
by mass spectrometry. In this report, we ﬁrst describe the char-
acterization of this cell line. Then, we focus our presentation
on the identiﬁcation and the description of the phosphoryla-
tion of serine 263. We demonstrate that this phosphorylation
is involved in preventing nuclear import of CDC25C.2. Results and discussion
2.1. Construction and characterization of a CDC25C
conditionally expressing cell line
We ﬁrst constructed and selected a U2OS cell line expressing
a HA and (His)6 epitope-tagged version of CDC25C under the
control of the tetracycline repressible promoter [30]. As illus-
trated in Fig. 1A, under inducing conditions (i.e. in the absence
of tetracycline), immunoﬂuorescence detection of CDC25C
using monoclonal anti-HA antibody indicated that expressed
CDC25C was, as expected, mostly located in the cytoplasm
of interphase cells and was abundant, especially in mitotic
cells. Western blot analysis with an anti-CDC25C antibody
(Fig. 1B) showed that in the absence of tetracycline this cellFig. 1. Characterization of a CDC25C conditionally expressing cell line. U2O
regulatable promoter were induced (tet) or not (+tet) during 24 h. (A) Im
antibodies to detect CDC25C expression and an Alexa-488 conjugated secon
(B) Western blotting performed with an anti-CDC25C antibody, the lower ba
(C) Cell cycle distribution performed by ﬂow cytometry analysis after propiline expressed a tagged CDC25C protein at the expected
molecular weight of 60 kDa. Analysis of cell cycle distribution
by ﬂow cytometry indicated that HA-CDC25C-His had no
obvious, deleterious eﬀect on cell cycle progression (Fig. 1C).
We next examined the potential eﬀect of CDC25C overex-
pression on the G2–M checkpoint activated by DNA damage.
To this aim, the cells were exposed for 1 h to 40 lM Etoposide
while the expression of HA-CDC25C-His was induced by tet-
racycline removal. As shown in Fig. 2A, 24 h after treatment
with Etoposide, control cells and cells overexpressing HA-
CDC25C-His accumulated with similar G2 DNA content.
Thus, the expression of the HA-CDC25C-His protein had no
obvious eﬀect on the G2 checkpoint and did not induce by-
pass.
In order to further ascertain that the G2 checkpoint was
fully functional, we used the previously described mitotic trap
assay [31,32] in which cells treated for 1 h with Etoposide were
further treated with nocodazole to trap into mitosis those that
eventually escaped the G2–M checkpoint. As shown in
Fig. 2B, as monitored with phosphorylated histone H3 detec-
tion, mitotic cells were essentially absent (0.5%) in CDC25C
expressing conditions. In contrast, when the cells were also
challenged with the checkpoint-abrogating compound UCN-
01, 15% of the cells bypassed the G2-checkpoint and entered
into mitosis where they were trapped by nocodazole.
2.2. Identiﬁcation of Serine 263 phosphorylation by mass
spectrometry analysis
A preparative culture of cells was grown in the absence of
tetracycline to induce the expression of HA-CDC25C-His for
24 h. Cells were treated or not with Etoposide essentially as de-
scribed in Fig. 2A. CDC25C was ﬁrst puriﬁed in denaturating
conditions on Ni-NTA aﬃnity matrix using a protocol that
was developed for the puriﬁcation and characterization of
post-translational modiﬁcations of CDC25B phosphatase
(Bouche´ et al., unpublished). After renaturation and a secondS cell expressing HA-CDC25C-His under the control of the tetracycline
munoﬂuorescence staining was performed with anti-HA monoclonal
dary antibody. DAPI was used to visualise nuclei. Scale bar is 10 lM.
nd shows endogenous CDC25C and the upper band HA-CDC25C-His.
dium iodide (PI) staining.
Fig. 2. Characterization of the G2 checkpoint of CDC25C conditionally expressing cell line. (A) To activate the G2/M checkpoint, cells were treated
with etoposide 40 lM for 1 h and the cell cycle was analyzed by ﬂow cytometry 24 h later. HA-CDC25C-His expression was induced by tetracycline
(Tet) removal. (B) Cells were treated with etoposide 40 lM 1 h and analyzed 24 h later. Nocodazole 250 ng/ml was added after the treatment with
Etoposide to trap the cells that bypass the G2–M checkpoint and enter mitosis. The checkpoint-abrogating drug UCN-01 100 nM was added to allow
bypass the G2/M checkpoint. The mitotic index (M%) was determined using detection of phosphorylated histone H3 antibody together with
propidium iodide staining by ﬂow cytometry analysis.
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CDC25C was digested in gel with trypsin and subjected to
mass spectrometry analysis.
A number of phosphorylated peptides were detected from
the two preparations of protein and several already described
phosphorylated sites were unambiguously identiﬁed after pep-
tide fragmentation (data not shown). In the CDC25C prepara-
tion puriﬁed from exponentially growing cells we identiﬁed a
new phosphorylation site at serine 263. Fig. 3 shows the spec-
trum of the mono-phosphorylated peptide 261-TVSLCDI-
TITQMLEEDSNQGHLIGDFSK-288. The observed
fragment ions conﬁrmed the peptide sequence and the presence
of a single phosphate group located on S263. y-ions series and
b2 fragment ion at m/z 201.13 indicated that S277, S287 and
T261 were not phosphorylated. Whereas b3 fragment ion at
m/z 368.12 conﬁrmed the phosphorylation on S263.2.3. Mutation of S263 aﬀects localization of CDC25C
To study the role of phosphorylation inCDC25C localization,
we prepared plasmids encoding HA-tagged CDC25C modiﬁed
at residue 263. Cells were transfected with either the wild type
or anon-phosphorylatablemutant of S263 (mutation to alanine)
and intracellular localization was scored 20 h after transfection
by evaluating the ratio between cytoplasmic and nuclear locali-
zation. As shown in Fig. 4A, we found that wild type CDC25C
was predominantly cytoplasmic in 90%of the cells, as previously
described. Treatment with 20 ng/ml leptomycin-B for 2 h led to
the accumulation of wild type CDC25C in the nucleus in 78%,
which is in agreement with the presence of an NES sequence
and a CRM1-dependent nuclear export mechanism.
In striking contrast we found that the S263A mutation led to
over 70% of cells displaying a pan cellular staining (Fig. 4B).
This was increased to 80% upon treatment with leptomycin-
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Fig. 3. Identiﬁcation of Serine 263 phosphorylation by mass spectrometry. MS/MS spectrum of the monophosphorylated peptide, 261-
TVSLCDITITQMLEEDSNQGHLIGDFSK-288 (triply charged precursor ion, (MH)3+, at m/z 1077.9) displays series of b- and y-ions (according to
Biemann’s nomenclature, [37]) indicating that the serine 263 residue is phosphorylated. *correspond to the loss of H3PO4.
Fig. 4. Serine 263 phosphorylation controls CDC25C cytoplasmic retention. (A) Cells were transiently transfected with HA-tagged wild type or
S263A CDC25C expressing plasmids, as indicated. The localization of the protein was examined 20 h after transfection on a minimum of 100 cells
and scored as relative abundance of the protein in the cytoplasm (C) and in the nucleus (N). Leptomycin-B (LMB) was added 2 h prior ﬁxation at the
concentration of 20 ng/ml. This set of data are representative of three independent experiments. S.D. error bars are indicated. (B) Cells were
transiently transfected with plasmids allowing the expression of wild-type CDC25C-HA or S263A CDC25C-HA. Representative examples with wild-
type or mutant proteins diﬀerentially located are shown in these panels. Cells transfected with CDC25C variants were detected by using an anti-HA
antibody. Scale bar is 10 lM.
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tion to putatively phosphomimetic residues (D and E) andfound that they behaved exactly as the S236A mutant (data
not shown).
P
CDC25C
P
CDC25C
Crm1
S263A S263A
Crm1
Cytoplasm Nucleus
Fig. 5. Working model. Phosphorylation of CDC25C by an unknown
kinase negatively controls translocation from the cytoplasm to the
nucleus. Mutation of S263 to alanine leads to a nuclear accumulation
that is further reinforced by leptomycin B indicating that Crm1-
dependent export is not aﬀected.
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All together these results indicate that phosphorylation of
serine 263 is involved in a mechanism that prevents CDC25C
from shuttling from the cytoplasm to the nucleus. Indeed, we
have shown that a mutation of serine 263 to a non-phosphoryl-
atable residue leads to the increase in nuclear abundance of
CDC25C. We have shown that this eﬀect is independent on
CRM1-dependent nuclear export, as the inhibition of this
exportin by leptomycin B (LMB) reinforced the nuclear accu-
mulation of CDC25C (Fig. 5). Serine 263 is located close to the
Nuclear Localization Sequence of CDC25C, therefore, it is
tempting to suggest that phosphorylation of S263 may aﬀect
the availability of the NLS sequence to the interaction with
importins. A similar regulation event has been reported in
the case of CDC25C serine 236 phosphorylation. Serine 236
is located just upstream of the NLS. When it is phosphorylated
by protein kinase CK2 the nuclear translocation of CDC25C is
enhanced and it accumulates in the nucleus [21]. Furthermore,
mutation of S236 to a phosphomimetic residue was found to
enhance nuclear accumulation of CDC25, in contrast to our
results with S263. In our work, mutation of serine 263 to either
aspartate or glutamate had invalidating eﬀects similar to those
reported with mutation to alanine (data not shown). It is pos-
sible that the presumed phosphomimetic mutation did not cor-
rectly mimic the phosphorylation event.
Alignment of CDC25C and CDC25B amino acid sequences
indicate that S263 is located within one of the few clusters of
conserved residues. The equivalent residue in CDC25B is ser-
ine 375, which has been found to be phosphorylated in expo-
nentially growing cells (Bouche´, JP. In preparation) and to
be a potential phosphorylation site for CHK1, pEG3, Aur-
ora-A and PKB-Akt kinases [33–36]. These observations sug-
gest that one or all of these kinases might also phosphorylate
CDC25C on serine 263. Further work will be required to eval-
uate this question both in vitro and in cultured cells.
A number of residues of CDC25C have been identiﬁed as
phospho-sites and shown to play a key regulatory role in the
control of the stability of CDC25C, its interaction with associ-ated-proteins, its activity and its intracellular localization. It is
likely, however, that this knowledge is incomplete and that a
number of additional phosphorylated sites will be identiﬁed
and their role clariﬁed. In this study, we have identiﬁed a
new phosphorylation site involved in the regulation of
CDC25C nucleo-cytoplasmic shuttling (Fig. 5). Serine 263 is
probably a part of a phosphorylation pattern resulting from
the combinatorial eﬀects of multiple kinases and phosphatases.
A major challenge will be to clarify their functional role of
each phosphorylation site amongst the complexity of this
phosphorylation pattern in association with physiological con-
ditions.4. Materials and methods
4.1. Cell culture conditions
U2OS cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% heat inactivated foetal calf serum
(Gibco), 100 lg/ml G418, 2 lg/ml tetracycline, penicillin (100 U/ml)
and streptomycin (100 lg/ml) in a humidiﬁed atmosphere containing
5% CO2 at 37 C. U2OS tTA were transiently transfected using
AMAXA following the manufacturer’s instructions.
4.1.1. Production and puriﬁcation of CDC25C. U2OS-tTA cells
expressing the tTA tetracycline repressor chimera (Clontech) were sta-
bly transfected with pPUHD10-HA3-CDC25B3-StrH6 and the protein
CDC25C was puriﬁed exactly as described for CDC25B (Bouche´ et al.,
unpublished).
Brieﬂy, U2OS-tTA cells stably transfected with pUHD10-HA3-
CDC25C-StrH6 were grown in complete DMEM medium with
100 lg/ml G418 and 2 lg/ml tetracycline. To express CDC25C, plates
were washed twice with PBS, and then grown in tetracycline-free
medium for 24 h. Cells were washed with cold PBS, very brieﬂy
rinsed with distilled water, then absolute ethanol was added and cells
were scrapped oﬀ the plates, collected by centrifugation and freeze-
dried. Denaturing solution (50 mM Tris–HCl, pH 8.0, 7.5 M urea,
1.5 M thio-urea, 4% CHAPS, 20 mM spermin, 5 mM 2-mercap-
toethanol) was added and proteins were solubilized with gentle
shaking for 16 h. The supernatant was adjusted to 5 mM imidazole
and HA-CDC25C-His was puriﬁed on Ni-NTA agarose column.
After iodoacetamide treatment, the eluate was diluted in renaturation
solution as described above, and HA-CDC25C-His was allowed to
bind to anti-HA Sepharose beads (Roche) for 24 h with gentle
mixing. Beads were then washed with binding buﬀer and taken up
in SDS–PAGE loading buﬀer, heated to 90 C and supernatant
was loaded onto a pre-made NU-PAGE Bis–Tris 4–12% gel (Invitro-
gen).
4.1.2. Mass spectrometry analysis. The Coomassie blue-stained
band of HA-CDC25C-His was excised from the gel and subjected to
in-gel tryptic digestion using trypsin (Promega). The tryptic digest
was analyzed by on-line capillary HPLC (LC Packings) coupled to a
nanospray Qq-Tof mass spectrometer (QSTAR Pulsar, Applied Bio-
systems). Peptides were separated on a 75 mm ID · 15 cm C18 Pep-
MapTM column after loading onto a 300 lM ID · 5 mm PepMap
C18 precolumn (LC Packings, Dionex). The ﬂow rate was set at
200 nl/min. Peptides were eluted using a 0–50% linear gradient of sol-
vent B in 100 min (solvent A was 0.2% formic acid in 5% acetonitrile
and solvent B was 0.2% formic acid in 90% acetonitrile). The mass
spectrometer was operated in positive ion mode at a 2.1 kV needle
voltage. MS and MS/MS data were continuously acquired in an infor-
mation-dependant acquisition mode consisting of a 10 s cycle time.
Within each cycle, a MS spectrum was accumulated for 1 s over the
range m/z 300–2000 followed by three MS/MS acquisitions of 3 s each
on the three most abundant ions in the MS spectrum. A 60 s dynamic
exclusion duration was employed to prevent repetitive selection of the
same ions within a preset time. MS/MS data were acquired using a 3 m/z
units ion isolation window. Collision energies were automatically ad-
justed according to the charge state and mass value of the precursor
ions and collision gas was N2. The MASCOT search engine (Matrix
Science, London, UK) was used for protein and phosphorylated pep-
tides identiﬁcation by searching against a non-redundant SwissProt
database with MS/MS spectra.
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Anti-HA antibodies (12CA5, Covance) used at the dilution of 1/1500
and the incubation was performed overnight at 4 C. Secondary anti-
bodies labelled with Alexa 488 or Alexa 594 (Molecular Probes) were
used at 1/1000 for 1 h at room temperature. DNA was visualised using
DAPI.
Images were acquired on a DMRXA2 or a DMIRE2 microscope
(Leica) using CCD cameras and subsequently processed by the Meta-
morph or the Qﬂuoro softwares.
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